Clinical trials: Parathyroid Dysfunction
End Stage Renal Disease
Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)
The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with ESRD receiving hemodialysis, on bio-intact…
- Trial name
- NCT00113945
- Testing
- Cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
22q11.2 Deletion Syndrome
Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome
Chromosome 22q11.2 deletion syndrome (22q11DS) is a neurogenetic condition associated with a high risk of psychiatric disorders, including schizophrenia spectrum disorders.
- Trial name
- NCT04647500
- Testing
- Concerta
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University of Geneva, Switzerland
DiGeorge Syndrome, Hypoparathyroidism
Parathyroid and Thymus Transplantation in DiGeorge #931
This study has three primary purposes: to assess parathyroid function after parathyroid transplantation in infants with Complete DiGeorge syndrome; to assess immune function development after transplantation; and, to assess…
- Conditions
- DiGeorge Syndrome, Hypoparathyroidism, Complete DiGeorge Syndrome
- Trial name
- NCT00566488
- Testing
- Thymus/Parathyroid Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Hyperparathyroidism
Swalqol in Primary Hyperparathyroidism
Swallow related quality of life before and after parathyroidectomy will be evaluated in patients with primary hyperparathyridism.
- Trial name
- NCT03968510
- Testing
- parathyroidectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Uşak University
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH)…
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT02282813
- Testing
- CTAP101 Capsules, Calcitriol, Doxercalciferol
- Volunteers
- 298 people
- Sponsor
- OPKO Health, Inc.
Hypoparathyroidism
Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults
This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia in adults with hypoparathyroidism.
- Trial name
- NCT06547151
- Testing
- AMOR-1, Crystalline Calcium Carbonate
- Where
- 9 sites in Israel
- Volunteers
- 62 people
- Sponsor
- Amorphical Ltd.
Hypoparathyroidism
ADD-ON Study to Existing Hypoparathyroidism Studies
The purpose of this protocol is to add on additional exploratory studies to investigate changes in bone quality parameters with PTH(1-84) treatment of hypoparathyroidism.
- Trial name
- NCT00856401
- Testing
- PTH1-84 in parent study
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy
The Effect of Etelcalcetide on CKD-MBD
The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and blood-vessels healthier.
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
- Trial name
- Parsabiv-MBD (NCT03960437)
- Testing
- Etelcalcetide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Thomas Nickolas, MD MS
Secondary Hyperparathyroidism, End-stage Kidney Disease
The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD
Patients with end-stage kidney disease (ESKD) have an increased risk of cardiovascular mortality. High parathyroid hormone (PTH) from secondary hyperparathyroidism leads to increased efflux of phosphate and calcium from bone…
- Trial name
- CaT50HD (NCT06398002)
- Testing
- Dialysate calcium 1.50 mmol/L
- Volunteers
- 48 people
- Sponsor
- Iain Bressendorff
DiGeorge Syndrome, 22q11.2 Deletion Syndrome
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people.
- Trial name
- NCT00556530
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Albert Einstein College of Medicine
Secondary Hyperparathyroidism
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic…
- Trial name
- NCT00463021
- Testing
- Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Primary Hyperparathyroidism
OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism
The purpose of this study is to determine whether osteoprotegerin and RANKL (receptor activator of nuclear factor-κB ligand) are involved in bone remodeling in patients with primary hyperparathyroidism (PHPT), and whether…
- Trial name
- NCT01889134
- Testing
- Sedron (alendronate), Parathyroidectomy
- Where
- Poland
- Volunteers
- 112 people
- Sponsor
- Wroclaw Medical University
Primary Hyperparathyroidism, Osteoporosis
Osteoporosis in Primary Hyperparathyroidism
Investigators will prospectively include 40 postmenopausal women with secondary osteoporosis due to primary hyperparathyroidism who have refused surgery.
- Trial name
- NCT04085419
- Testing
- Denosumab 60 MG/ML Prefilled Syringe [Prolia], Zoledronic Acid
- Where
- Slovenia
- Volunteers
- 40 people
- Sponsor
- University Medical Centre Ljubljana
Renal Osteodystrophy
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD
The proposed 6 month pilot and feasibility randomized trial will evaluate LMMS as an anabolic stimulus to bone in 30 adults on maintenance hemodialysis.
- Trial name
- NCT00364234
- Testing
- Low magnitude mechanical stimuli
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
The study aims to identify predictors of disease in patients with hyperparathyroidism (HPTH) who undergo surgery.
- Conditions
- Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism
- Trial name
- NCT03053999
- Testing
- Genome Sequencing, Data Review
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Diseases, Parathyroid Diseases
Ropivacaine Plus Magnesium Sulphate Infiltration
In the domain of endocrine gland surgery, thyroidectomy is the most common procedure. Patients report moderate to severe discomfort postoperatively, which is induced by a variety of mechanisms, the most common of which are…
- Conditions
- Thyroid Diseases, Parathyroid Diseases, Postoperative Pain, Anesthesia, Local
- Trial name
- NCT05294393
- Testing
- Ropivacaine 10%, Ropivacaine 10% plus magnesium sulphate 10mg/kg
- Where
- Greece
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Primary Hyperparathyroidism
NIRAF-camera Versus Conventional Surgery in Preoperative Imaging Negative Primary Hyperparathyroidism
Primary hyperparathyroidism (PHPT) is a prevalent endocrine disorder, with an estimated prevalence of 0.86% in the United States. The only definitive treatment for PHPT is parathyroidectomy.
- Trial name
- NCT07812649
- Testing
- NIRAF-camera
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Cleveland Clinic
Breast Carcinoma, Prostate Cancer Surgery
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease.
- Conditions
- Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer, Parathyroid Adenomas
- Trial name
- NCT06835426
- Testing
- Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen imager
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Hypoparathyroidism
A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism
XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism.
- Trial name
- NCT07540286
- Testing
- Single subcutaneous injection, Multiple subcutaneous injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Hypoparathyroidism
Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism
A Randomized, active comparator, two-part, partial crossover design. The study is designed to assess the pharmacokinetics and pharmacodynamics of EnteraBio's Oral PTH(1-34) [EB612 (EBP05)] in adult patients with…
- Trial name
- NCT03516773
- Testing
- EB612 (EBP05), NATPARA/NATPAR
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Entera Bio Ltd.